Advertisement

Research Article Free access | 10.1172/JCI115154

Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

S Gupta, J Kim, and S Gollapudi

Division of Basic and Clinical Immunology, University of California, Irvine 92717.

Find articles by Gupta, S. in: JCI | PubMed | Google Scholar

Division of Basic and Clinical Immunology, University of California, Irvine 92717.

Find articles by Kim, J. in: JCI | PubMed | Google Scholar

Division of Basic and Clinical Immunology, University of California, Irvine 92717.

Find articles by Gollapudi, S. in: JCI | PubMed | Google Scholar

Published April 1, 1991 - More info

Published in Volume 87, Issue 4 on April 1, 1991
J Clin Invest. 1991;87(4):1467–1469. https://doi.org/10.1172/JCI115154.
© 1991 The American Society for Clinical Investigation
Published April 1, 1991 - Version history
View PDF
Abstract

Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (April 1, 1991): No description
Advertisement
Advertisement